Brief: Metavia Announces $10 Million Private Placement Priced At-The-Market Under Nasdaq Rules
MetaVia Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential
U.S. STOCKS ON THE MOVE-Dow, Nike, Coty
U.S. STOCKS ON THE MOVE-Caterpillar, Netflix, Bank of America
U.S. STOCKS ON THE MOVE-Rocket Lab, Boeing, Citigroup
MetaVia rises after experimental obesity drug shows promise in early-stage study
Brief: Metavia Announces Positive Top-Line Data From The 4-Week Phase 1 Mad Trial Of Da-1726
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy
U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent
Brief: Metavia Announces Positive Top-Line Results From Its Phase 2A Clinical Trial Of Da-1241 In Patients With Presumed MASH
Brief: Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To Metavia
NeuroBo Pharmaceuticals Inc expected to post a loss of 89 cents a share - Earnings Preview
Brief: Neurobo Pharmaceuticals Completes Last Patient Last Visit In Its Phase 2A Clinical Trial Evaluating Da-1241 For The Treatment Of Mash
U.S. STOCKS ON THE MOVE-Emeren Group, Hess, Chevron
U.S. STOCKS ON THE MOVE-CVS Health, Estee Lauder, NeuroBo Pharma
Brief: Neurobo Pharmaceuticals Announces Positive Top-Line Data From The SAD Part 1 Of Phase 1 Clinical Trial Evaluating DA-1726
NeuroBo Pharma rises as obesity drug meets main goal in early-stage study
NeuroBo Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary